Tenascin-N Activators
Tenascin-N Activators are a set of chemical compounds that enhance the functional activity of Tenascin-N through various specific signaling pathways. Compounds like Forskolin and 8-Bromo-cAMP work by increasing cAMP levels in the cell, which in turn activate PKA. The activated PKA has the ability to phosphorylate substrates that are involved in cell adhesion and matrix assembly, processes where Tenascin-N plays a critical role. Similarly, the calcium ionophore Ionomycin raises intracellular calcium levels, activating calcium-dependent signaling pathways that could influence the extracellular matrix and, in turn, enhance Tenascin-N's function within it. PKC activators such as Phorbol 12-myristate 13-acetate (PMA) and inhibitors like Bisindolylmaleimide I alter the phosphorylation state of proteins involved in the extracellular matrix, leading to an enhanced role for Tenascin-N in matrix organization and cell-matrix signaling.
Additional compounds including LY294002, PD98059, SB203580, U0126, Sp600125, Gö6976, and Wortmannin modulate various kinases such asPI3K, MEK, p38 MAPK, and JNK, which are central to cellular signaling pathways that regulate processes such as cell adhesion, migration, and tissue remodeling. LY294002 and Wortmannin, both PI3K inhibitors, may downregulate competitive AKT signaling, thereby indirectly promoting the activity of Tenascin-N in cell adhesion and migration. MEK inhibitors, PD98059 and U0126, reduce ERK activation, which can shift the balance towards Tenascin-N-mediated signaling in matrix integrity. The inhibition of p38 MAPK by SB203580 may favor Tenascin-N's involvement during tissue remodeling, while Sp600125's inhibition of JNK could promote Tenascin-N's role in neuronal development and axonal growth. Gö6976, a classic PKC inhibitor, might enhance Tenascin-N's activity by attenuating competitive PKC substrate phosphorylation, which otherwise could dampen Tenascin-N's signaling pathways. Collectively, these chemicals act on distinct but interrelated signaling pathways to enhance the functional activity of Tenascin-N, ensuring its pivotal role in extracellular matrix dynamics and cell-matrix interactions is supported.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, leading to increased cAMP levels. Elevated cAMP activates PKA, which then can phosphorylate various substrates, potentially including those that might interact with Tenascin-N, leading to its functional enhancement in cellular processes such as cell adhesion. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP is a cell-permeable cAMP analog that activates PKA. PKA activation can enhance Tenascin-N interactions with other extracellular matrix proteins, thereby strengthening its role in matrix assembly and cell-matrix signaling. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore, which increases intracellular calcium levels, thereby activating calcium-dependent signaling pathways. These pathways can lead to the phosphorylation of proteins that regulate the extracellular matrix where Tenascin-N is a critical component. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a PKC inhibitor that can increase the activity of PKC substrates by reducing their phosphorylation. This might indirectly enhance Tenascin-N's function by shifting the balance of cellular signaling towards pathways where Tenascin-N is active. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent PKC activator. By activating PKC, it may enhance the phosphorylation of proteins involved in the structural integrity of the matrix, indirectly promoting Tenascin-N's role in matrix organization. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, potentially reducing competitive signaling pathways and indirectly enhancing those pathways where Tenascin-N is involved, such as those regulating cellular adhesion and migration. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an MEK inhibitor, which could lead to reduced ERK activation. This could shift cellular signaling dynamics in favor of Tenascin-N mediated pathways involved in the structural integrity of the matrix. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which can modulate cellular responses to stress and inflammation. Inhibition of p38 may favor Tenascin-N's role in the extracellular matrix during tissue remodeling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Sp600125 is an inhibitor of JNK, which may shift the cellular signaling balance to enhance pathways where Tenascin-N has a functional role, such as in neuronal development and axonal growth. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
Gö6976 is a classic PKC inhibitor, which may indirectly enhance Tenascin-N's functional activity by reducing phosphorylation of PKC substrates that are involved in competitive signaling pathways. | ||||||